DOCSLIB.ORG

Of Alcoholism Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Of Alcoholism Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo M Acamprosate in Relapse Prevention of Alcoholism Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo M. Soyka (Ed.) Acamprosate in Relapse Prevention of Alcoholism With 47 Figures and 16 Tables , Springer PD Dr. Michael Soyka Psychiatrische Klinik und Poliklinik der Universitat Miinchen NuBbaumstr. 7 80336 Miinchen, Germany ISBN-13 :978-3-642-80195-2 e-ISBN-13 :978-3-642-80193-8 DOl: 10.1007/978-3-642-80193-8 Library of Congress Cataloging-in-Publication Data. Acamprosate in relapse prevention of alcoholism! M.Soyka,ed. p. cm. Includes bibliographical references and index. ISBN-13:978-3-642-80195-2 (hardcover)!. Alcoholism - Chemotherapy. 2. Acamprosate. 3. Alcoholism - Relapse - Chemoprevention. I. Soyka. M. (Michael). 1959- . RC565.A27 1996 96-12923 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1996 Softcover reprint of the hardcover 1st edition 1996 The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regnlations and therefore free for general use. Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consnlting the relevant literature. Cover design: Design & Production, Heidelberg Typesetting: Scientific Publishing Services (P) Ltd, Madras SPIN: 10525036 25!3134!SPS - 5 4 3 2 1 0 - Printed on acid-free paper Preface Alcoholism is the most common psychiatric disorder in most developed countries and a large number of developing countries, as numerous epide­ miological and clinical studies have demonstrated. Alcoholism affects the pa­ tient's life in many ways and may induce various medical and psychiatric sequelae. Over the past few decades, there have been continued efforts to improve the treatment of alcoholics. Thus different psychotherapeutic ap­ proaches have been designed and applied to alcohol treatment. Follow-up studies have demonstrated alcohol treatment to be efficient, with a significant number of patients remaining abstinent. Still, even after long-term inpatient treatment, more than 50% of the patients relapse. Relapse prevention remains a major challenge in the treatment of alcohol­ ism. Various forms of relapse prevention including group therapy, individual psychotherapy with supportive or behavioral therapy, contingency contracting, and self-help groups have been advocated. All seem to be helpful in some cases and unsuccessful in a significant number of others. Apart from chemical aversion therapy, various psychopharmacological in­ terventions have been tried for relapse prevention, all with limited or no success. In recent years, our knowledge of the neurochemical and neurobio­ logical basis of alcoholism and craving for alcohol has increased significantly. The glutamatergic system has been a major focus, and acamprosate, a mod­ ulator of the glutamatergic system, is one of the most promising new phar­ macological agents used in relapse prevention of alcoholism. In September 1995, a satellite symposium was held prior to the ESBRA congress to evaluate and discuss preclinical and clinical studies conducted with acamprosate. The proceedings of this symposium are summarized in this book, which also contains some important new papers on the pharmacology and clinical efficacy of acamprosate. The editor feels that this book offers a comprehensive overview on the most important studies on acamprosate conducted so far. It is hoped that many patients will benefit from anticraving drugs such as acamprosate, and perhaps this agent will help improve the treatment outcome in alcoholic patients. Munich Michael Soyka February 1996 Contents Ethanol and the NMDA Receptor: Implications for Intoxication, Tolerance, Dependence, and Alcoholic Brain Damage D.M. Lovinger ......................................... 1 The Neurobiology of Craving: Potential Mechanisms for Acamprosate J. Littleton, M. al Qatari, and H. Little .. 27 Pharmacodynamics and Pharmacokinetics of Acamprosate: An Overview P. Durbin, T. Hulot, and S. Chabac .......................... 47 Actions of Acamprosate on Neurons of the Central Nervous System W. Zieglgansberger, C. Hauser, C. Wetzel, J. Putzke, G.R. Siggins, and R. Spanagel .............................. 65 Acamprosate Decreases Alcohol Behavioral Dependence and Hypermotility After Alcohol Withdrawal But Increases Inhibitory Amino-Acids in Alcohol-Attracted Inbred Rats Using Microdialysis of the Nucleus Accumbens P. De Witte, A. Dahchour, E. Quertemont, P. Durbin, and S. Chabac ......................................... 71 Event-Related Potentials and EEG as Indicators of Central Neurophysiological Effects of Acamprosate U. Hegerl, M. Soyka, J. Gallinat, S. Ufer, U. PreuB, R. Bottlender, and H.-J. Moller ............................. 93 Effects of Acamprosate on Verbal Learning in Healthy Young Subjects N. Kathmann, M. Soyka, J. Gallinat, and U. Hegerl . 105 Acamprosate in Clinical Practice: The French Experience H.-J. Aubin ........................................... 111 VIII Contents Acamprosate Clinical Trials: Methodological Considerations for Assessment of Drinking Behaviour A.S. Potgieter and P. Lehert ............................... 121 Acamprosate in the Treatment of Alcohol Dependence: A 6-Month Postdetoxification Study I. Pelc, o. Le Bon, P. Lehert, and P. Verbanck ................. 133 Contribution of Acamprosate in Maintaining Abstinence in Weaned Alcohol-Dependent Patients: Additional Results of the Second French Multicentre Study F. Paille, P. Parot, and C. Gillet . 143 Clinical Efficacy of Acamprosate in the Treatment of Alcoholism M. Soyka ............................................. 155 Subject Index . .. 173 List of Contributors al Qatari, M., Pharmacology Group, Kings College, Manresa Road, London SW3 6LX, UK Aubin, H.-J., Centre d'Alcoologie, Hopital Emile Roux, 94456 Limeil-Brevannes Cedex, France Bottlender, R., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, NuBbaumstr. 7, 80336 Munchen, Germany Chabac, S., Groupe LIPHA, DiMI, 34 rue St-Romain, 69379 Lyon Cedex 8, France Dahchour, A., Laboratoire de Psychobiologie, Universite de Louvain, Place Croix-du-Sud, 1348 Louvain-Ia-Neuve, Belgium De Witte, P., Laboratoire de Psychobiologie, Universite de Louvain, Place Croix-du-Sud, 1348 Louvain-Ia-Neuve, Belgium Durbin, P., Groupe LIPHA, Centre de Recherche et de Developpement, 115 avenue Lacassagne, 69003 Lyon, France Gallinat, J., Psychiatrische Klinik der Ludwig-Maximillians-Universitat, NuBbaumstr. 7, 80336 Munchen, Germany Gillet, C., Centre d'Alcoologie, Hopital Fournier, 36 quai de la Bataille, 54035 NancyCedex, France Hauser, C., Max-Planck-Institut fUr Psychiatrie, Klinisches Institut, Kraepelinstr. 2, 80804 Munchen, Germany Hegerl, U., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, Nuf3baumstr. 7, 80336 Munchen, Germany Hulot, T., Groupe LIPHA, Centre de Recherche et de Developpement, 115 avenue Lacassagne, 69003 Lyon, France Kathmann, N., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, NuBbaumstr. 7, 80336 Munchen, Germany x List of Contributors Le Bon, 0., Laboratoire de Psychobiologie Medicale et d' Alcoologie, Universite Libre de Bruxelles (Campus Brugmann), Place Van Gehuchten 4, 1020 Brussels, Belgium Lehert, P., Departement de Sciences Economiques Appliquees, Facultes Catholiques de Mons, 7000 Mons, Belgium Little, H., Psychology Department, University of Durham, Durham, UK Littleton, J., Pharmacology Group, Kings College, Manresa Road, London SW3 6LX, UK Lovinger, D.M., Department of Molecular Physiology and Biophysics and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, USA Moller, H.-J., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, NuBbaumstr. 7,80336 Miinchen, Germany Paille, F., Centre d'Alcoologie, Hopital Fournier, 36 quai de la Bataille, 54035 Nancy Cedex, France Parot, P., Pharmaceutical Consultant, 12, avenue G. Pompidon, 92800 Puteaux, France Pelc, I., Laboratoire de Psychologie Medicale et d'Alcoologie, Universite Libre de Bruxelles (Campus Brugmann), Place Van Gehuchten 4, 1020 Brussels, Belgium Potgieter, A.S., Groupe LIPHA, 34 rue St-Romain, 69379 Lyon Cedex 8, France PreuB, U., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, NuBbaumstr. 7, 80336 Miinchen, Germany Putzke, J., Max-Planck-Institut fur Psychiatrie, Klinisches Institut, Kraepelinstr. 2, 80804 Miinchen, Germany Quertemont, E., Laboratoire de Psychobiologie, Universite de Louvain, Place Croix-du-Sud, 1348 Louvain-Ia-Neuve, Belgium Siggins, G.R., Department of Neuropharmacology, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA Soyka, M., Psychiatrische Klinik der Ludwig-Maximilians-Universitat, NuBbaumstr. 7, 80336 Miinchen, Germany
Load more

Recommended publications
  • Perceptions of Powdered Alcohol and Intentions to Use: an Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults
    Beverages 2015, 1, 329-340; doi:10.3390/beverages1040329 OPEN ACCESS beverages ISSN 2306-5710 www.mdpi.com/journal/beverages Article Perceptions of Powdered Alcohol and Intentions to Use: An Exploratory Qualitative Assessment of Potential Palcohol Use by Young Adults John Stogner 1,*, Julie M. Baldwin 2, Timothy Brown 3 and Taylor Chick 1 1 Department of Criminal Justice and Criminology, University of North Carolina at Charlotte, 9201 University Boulevard., Charlotte, NC 28223, USA; E-Mail: [email protected] 2 Department of Criminology and Criminal Justice, Missouri State University, 901 S. National Strong Hall Room. 226, Springfield, MO 65897, USA; E-Mail: [email protected] 3 Department of Criminal Justice, University of Arkansas at Little Rock, Ross Hall 5th Floor, Little Rock, AR 72204, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-704-687-8446; Fax: +1-704-687-5285. Academic Editor: Edgar Chambers IV Received: 14 October 2015 / Accepted: 17 November 2015 / Published: 1 December 2015 Abstract: While there seems to be growing media intrigue over atypical forms of alcohol use, the utilization of the majority of novel consumption methods (e.g., eyeballing, slimming, alcohol without liquid (AWOL)) seems minimal. In 2014, however, several outlets suggested that powdered alcohol would soon surface as a threat to public safety. The impetus of these fears was the Alcohol and Tobacco Tax and Trade Bureau’s approval for Lipsmark LLC to package a powdered alcohol product named “Palcohol”. Palcohol has yet to reach store shelves, but public outcry has been intense.
    [Show full text]
  • Methanol Interim AEGL Document
    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Choctaw Nation Criminal Code
    Choctaw Nation Criminal Code Table of Contents Part I. In General ........................................................................................................................ 38 Chapter 1. Preliminary Provisions ............................................................................................ 38 Section 1. Title of code ............................................................................................................. 38 Section 2. Criminal acts are only those prescribed ................................................................... 38 Section 3. Crime and public offense defined ............................................................................ 38 Section 4. Crimes classified ...................................................................................................... 38 Section 5. Felony defined .......................................................................................................... 39 Section 6. Misdemeanor defined ............................................................................................... 39 Section 7. Objects of criminal code .......................................................................................... 39 Section 8. Conviction must precede punishment ...................................................................... 39 Section 9. Punishment of felonies ............................................................................................. 39 Section 10. Punishment of misdemeanor .................................................................................
    [Show full text]
  • METHANOL 6 (CAS Reg
    1 INTERIM 1: 1/2003 2 INTERIM 2: 2/2005 3 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS 4 (AEGLs) 5 METHANOL 6 (CAS Reg. No. 67-56-1) 7 For 8 NAS/COT Subcommittee for AEGLs 9 February 2005 METHANOL Interim 2: 2/2005 10 PREFACE 11 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the 12 National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 13 (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and 14 other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 15 AEGLs represent threshold exposure limits for the general public and are applicable to emergency 16 exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as 17 appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 18 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the 19 recommended exposure levels are applicable to the general population including infants and children, and 20 other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: 21 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 22 is predicted that the general population, including susceptible individuals, could experience notable 23 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling 24 and are transient and reversible upon cessation of exposure.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet Al
    US009248195B2 (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet al. (45) Date of Patent: *Feb. 2, 2016 (54) ABUSE-DETERRENT PHARMACEUTICAL (52) U.S. Cl. COMPOSITIONS OF OPODS AND OTHER CPC ............... A61K 47/46 (2013.01); A61 K9/1617 DRUGS (2013.01); A61 K9/5026 (2013.01); A61 K 31/485 (2013.01); A61K 45/06 (2013.01); (71) Applicant: COLLEGIUM PHARMACEUTICAL, A61K47/12 (2013.01) INC., Canton, MA (US) (58) Field of Classification Search (72) Inventors: Roman V. Rariy, Allston, MA (US); CPC ......... A61K 9/141; A61 K9/148: A61 K9/20: Alison B. Fleming, North Attleboro, MA A61 K9/48: A61 K9/145; A61 K9/16: A61 K (US); Jane Hirsh, Wellesley, MA (US); 9/1617; A61 K9/50: A61 K9/2013: A61 K Alexander M. Klibanov, Boston, MA 9/2077; A61K31/135; A61K31/485 (US) See application file for complete search history. (73) Assignee: Collegium Pharmaceutical, Inc., (56) References Cited Canton, MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 2,404,319 A 7, 1946 Shelton U.S.C. 154(b) by 114 days. 3,015,128 A 1/1962 Somerville, Jr. 3,336,200 A 8, 1967 Krause et al. This patent is Subject to a terminal dis 3,773.955 A 11/1973 Pachter et al. claimer. 3,966,940 A 6, 1976 Pachter et al. 3,980,766 A 9, 1976 Shaw et al. (21) Appl. No.: 14/054,513 4,070,494 A 1/1978 Hoffmeister et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,771,707 B2 Hirsh Et Al
    US00777 1707B2 (12) United States Patent (10) Patent No.: US 7,771,707 B2 Hirsh et al. (45) Date of Patent: *Aug. 10, 2010 (54) ABUSE-DETERRENT DRUG 6,156,764 A 12/2000 Asmussen et al. FORMULATIONS 6,162,467 A 12/2000 Miller et al. 6,261,599 B1 7/2001 Oshlack et al. (75) Inventors: Jane C. Hirsh, Wellesley, MA (US); 6,277.384 B1 8/2001 .N. Alison B. Fleming, North Attleboro, MA 4 (US); Roman V. Rariy, Allston, MA 6,294,195 B1 9, 2001 Oshlack et al. (US); Alexander M. Klibanov, Newton, 6,309.668 B1 10/2001 Bastin et al. MA (US) 6,310,072 B1 10/2001 Smith et al. 6,328,979 B1 12/2001 Yamashita et al. (73) Assignee: Collegium Pharmaceutical, Inc., 6,335,033 B2 1/2002 Oshlack et al. Cumberland, RI (US) 6,375,957 B1 4/2002 Kaiko et al. (*) Notice: Subject to any disclaimer, the term of this 6,475,494 B2 11/2002 KaikoakO etC. al. patent is extended or adjusted under 35 U.S.C. 154(b) by 1058 days. This patent is Subject to a terminal dis- (Continued) claimer. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/149,867 EP O 253 104 1, 1988 (22) Filed: Jun. 10, 2005 (65) Prior Publication Data (Continued) US 2005/0281748A1 Dec. 22, 2005 OTHER PUBLICATIONS Related U.S. Application Data Cortesi, et al., Sugar Cross-linked gelatin for controlled release: (60) Provisional application No. 60/579,191, filed on Jun microspheres and disksBiomaterials, 19:1641-1649 (1998).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]